IP Library Granted Patent US 11,274,286
Granted Patent B2
US 11,274,286 · App. 16/460,118 · Granted Mar 15, 2022

Engineered deoxyribose-phosphate aldolases

Inventors: Da Duan (Newark, CA); Oscar Alvizo (Fremont, CA); Jovana Nazor (Milpitas, CA); Harvinder Chagger Maniar (Hayward, CA); James Nicholas Riggins (San Francisco, CA); Jonathan Vroom (South San Francisco, CA); Santhosh Sivaramakrishnan (Redwood City, CA); Hao Yang (Rahway, NJ); Anna Fryszkowska (New York, NY); Mark A. Huffman (Rahway, NJ); Joshua N. Kolev (Rahway, NJ); Iman Farasat (Rahway, NJ); Agustina Rodriguez-Granillo (Rahway, NJ); Deeptak Verma (Rahway, NJ)
Assignee: Codexis, Inc.
C12N9/88C12N15/63C12P21/02C12Y401/02004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,274,286
App. No.
16/460,118
Granted
Mar 15, 2022
Kind
B2
Abstract

The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.

Claims (5)

1. An engineered deoxyribose-phosphate aldolase comprising a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 2 or a functional fragment thereof, wherein said engineered deoxyribose-phosphate aldolase comprises a substitution in said polypeptide sequence of X145C/R/K, and wherein said engineered deoxyribose-phosphate aldolase has at least 1.2 fold increased activity on (R)-2-ethynyl-glyceraldehyde as compared to the wild-type polypeptide sequence of SEQ ID NO:2, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2.

2. The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence that is at least 95% identical to the sequence of at least one engineered deoxyribose-phosphate aldolase variant set forth in the even numbered sequences of SEQ ID NOS: 6, 12, 42, 104, or 140-478.

3. The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence set forth in the even numbered sequences of SEQ ID NOS: 6, 12, 42, 104, or and 140-478.

4. The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase is purified.

5. A composition comprising at least one engineered deoxyribose-phosphate aldolase provided in claim 1 .

Assignments (2)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: DUAN, DA; ALVIZO, OSCAR; NAZOR, JOVANA; MANIAR, HARVINDER CHAGGER; RIGGINS, JAMES NICHOLAS; VROOM, JONATHAN; SIVARAMAKRISHNAN, SANTHOSH
To: CODEXIS, INC.
Reel/Frame 050097/0850 →
Continuity (3)
Provisional Application 62695520 · Jul 9, 2018
Provisional Application 62822273 · Mar 22, 2019
Related Publication 20200010868A1 · Jan 9, 2020
Cited By (1)
US 12,460,195